Barclays’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-253,084
| Closed | -$2.27M | – | 7161 |
|
|
2016
Q3 | $2.27M | Buy |
+253,084
| New | +$1.8M | ﹤0.01% | 1897 |
|
|
2016
Q2 | – | Sell |
-12
| Closed | -$62 | – | 7021 |
|
|
2016
Q1 | $0 | Sell |
12
-1,029
| -99% | -$4.14K | ﹤0.01% | 6907 |
|
|
2015
Q4 | $4K | Sell |
1,041
-27,095
| -96% | -$157K | ﹤0.01% | 5654 |
|
|
2015
Q3 | $170K | Buy |
28,136
+26,525
| +1,646% | +$325K | ﹤0.01% | 4258 |
|
|
2015
Q2 | $24K | Sell |
1,611
-1,551
| -49% | -$18.8K | ﹤0.01% | 5586 |
|
|
2015
Q1 | $32K | Sell |
3,162
-64,845
| -95% | -$662K | ﹤0.01% | 5593 |
|
|
2014
Q4 | $681K | Buy |
68,007
+61,140
| +890% | +$597K | ﹤0.01% | 3553 |
|
|
2014
Q3 | $62K | Sell |
6,867
-6,476
| -49% | -$66.1K | ﹤0.01% | 5711 |
|
|
2014
Q2 | $147K | Buy |
13,343
+3,672
| +38% | +$33.4K | ﹤0.01% | 5131 |
|
|
2014
Q1 | $96K | Buy |
9,671
+2,984
| +45% | +$43.1K | ﹤0.01% | 5497 |
|
|
2013
Q4 | $86K | Sell |
6,687
-7,927
| -54% | -$109K | ﹤0.01% | 5784 |
|
|
2013
Q3 | $205K | Buy |
14,614
+3,815
| +35% | +$45.7K | ﹤0.01% | 5013 |
|
|
2013
Q2 | $101K | Buy |
+10,799
| New | +$73.1K | ﹤0.01% | 5782 |
|
Barclays's RPTP Position: Q4 2016 in Review
Barclays sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 253,084 shares — an estimated $2.27M sold.
Barclays first reported a position in RPTP in Q2 2013 and held it in 13 quarters. The position peaked at $2.27M in Q3 2016. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Barclays reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Barclays sold 253,084 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $2.27M.
- Barclays first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Barclays's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $2.27M in Q3 2016.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Barclays's 13F filing for Q4 2016, filed 14 Feb 2017.